Seattle's VC-Cum-Incubator Accelerator Pockets $22.5M to Fund New Biotechs | GenomeWeb
Accelerator Corporation, a privately held Seattle-based biotechnology investment firm, has secured $22.5 million in new venture capital commitments to help it fund emerging biotechnology companies.
Accelerator, which employs a venture capital-cum-incubator model to nurture early-stage biotech companies, expects to use the new commitments to fund as many as six companies in the next two to three years, with a particular eye toward university spinouts, executives from the company said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.